Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism

Stock Track

04/27

Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.

The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.

Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1120458534"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120458534\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120458534?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120458534","market":"hk","top_or_hot":-1,"title":"Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism","media":"Stock Track","content":"<p>Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.</p><p>The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.</p><p>Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-27 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.</p><p>The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.</p><p>Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1120458534","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120458534","pubTimestamp":1777254687,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"个股赛道|首家券商覆盖叠加管线乐观海西药业盘中大涨14.56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}